Kentaro Hayashi joined Synplogen in 2020, and he is currently head of the DNA synthesis business unit and responsible for R&D, DNA manufacturing, and marketing activities for the DNA synthesis service. Before joining Synplogen, he was a post-doc at UMass Chan Medical School, and in 2017 he joined Eli Lilly for medical affairs in the diabetes area. Kentaro earned his Ph.D. at Keio University, where he is dedicated to cancer research using a systems biology approach, led by Dr. Kumar Selvarajoo.